Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Rani Therapeutics Holdings Inc. Class A Common Stock
RANI | US
2.57
USD-0.11
-4.10%
RANI | US
About Rani Therapeutics Holdings Inc. Class A Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
2.57
Open
2.70
High
2.72
Low
2.55
Rani Therapeutics Holdings Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule a drug-agnostic oral delivery platform to deliver a variety of drug substances including large molecules such as peptides proteins and antibodies. Its product pipeline includes RT-101 an octreotide which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102 a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105 an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110 a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111 an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company was incorporated in 2012 and is headquartered in San Jose California.
View LessRANI | US
Risk
265.7
Sharpe
0.17
Luna's Score
33/100
Recommendation
Sell
Luna says (RANI | US)
What's Working
Low Market Beta (-0.4 to 0.8)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
357.9%1 month
265.7%3 months
161.3%6 months
129.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
30.14
Debt to equity
12.43
Debt to assets
0.81
Ent. to EBITDA
-1.42
Ent. to rev.
84.28
PEG
-
Other Fundamentals
EBITDA
-56.90M
MarketCap
148.72M
MarketCap(USD)
148.72M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-225.35
Short ratio
10.51
Short perc.
4.89
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.73
Range1M
1.75
Range3M
1.75
Volumes: Market Activity
Rel. volume
0.30
Price X volume
3.43M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.42 | - | Cheaper |
| Ent. to Revenue | 84.28 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 30.14 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 161.26 | - | Riskier |
| Debt to Equity | 12.43 | -1.23 | Expensive |
| Debt to Assets | 0.81 | 0.25 | Expensive |
| Market Cap | 148.72M | - | Emerging |
